CN105724653A - 一种左旋肉碱绿茶减肥冲剂及其制备方法 - Google Patents
一种左旋肉碱绿茶减肥冲剂及其制备方法 Download PDFInfo
- Publication number
- CN105724653A CN105724653A CN201610122983.5A CN201610122983A CN105724653A CN 105724653 A CN105724653 A CN 105724653A CN 201610122983 A CN201610122983 A CN 201610122983A CN 105724653 A CN105724653 A CN 105724653A
- Authority
- CN
- China
- Prior art keywords
- parts
- carnitine
- powder
- green tea
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 44
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 20
- 235000009569 green tea Nutrition 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000008187 granular material Substances 0.000 title abstract 4
- 239000000843 powder Substances 0.000 claims abstract description 66
- 229920002752 Konjac Polymers 0.000 claims abstract description 27
- 235000013616 tea Nutrition 0.000 claims abstract description 27
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 24
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 23
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 20
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 20
- 229940094952 green tea extract Drugs 0.000 claims abstract description 20
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 20
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 18
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 18
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 18
- 229930195725 Mannitol Natural products 0.000 claims abstract description 18
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 18
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 18
- 239000000594 mannitol Substances 0.000 claims abstract description 18
- 235000010355 mannitol Nutrition 0.000 claims abstract description 18
- 229940013618 stevioside Drugs 0.000 claims abstract description 18
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019202 steviosides Nutrition 0.000 claims abstract description 18
- 235000005911 diet Nutrition 0.000 claims abstract description 12
- 230000037213 diet Effects 0.000 claims abstract description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- -1 concentration Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229960001855 mannitol Drugs 0.000 claims description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 235000006468 Thea sinensis Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000005238 degreasing Methods 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 2
- 229940046892 lead acetate Drugs 0.000 claims description 2
- RVPVRDXYQKGNMQ-UHFFFAOYSA-N lead(2+) Chemical compound [Pb+2] RVPVRDXYQKGNMQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000020333 oolong tea Nutrition 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 abstract description 17
- 235000020824 obesity Nutrition 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 3
- 230000005802 health problem Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 229920000057 Mannan Polymers 0.000 abstract 1
- 235000010485 konjac Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 17
- 239000003814 drug Substances 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229960004425 sibutramine Drugs 0.000 description 6
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 229960001243 orlistat Drugs 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- IWQURBSTAIRNAE-UHFFFAOYSA-N Alismoxide Chemical compound CC1(O)CCC(C(C)C)=CC2C(O)(C)CCC21 IWQURBSTAIRNAE-UHFFFAOYSA-N 0.000 description 2
- ZCKAMNXUHHNZLN-UHFFFAOYSA-N Chlorphentermine Chemical compound CC(C)(N)CC1=CC=C(Cl)C=C1 ZCKAMNXUHHNZLN-UHFFFAOYSA-N 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229950003745 benzfetamine Drugs 0.000 description 2
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940060038 chlorine Drugs 0.000 description 2
- 229950007046 chlorphentermine Drugs 0.000 description 2
- 229960002492 clobenzorex Drugs 0.000 description 2
- LRXXRIXDSAEIOR-ZDUSSCGKSA-N clobenzorex Chemical compound C([C@H](C)NCC=1C(=CC=CC=1)Cl)C1=CC=CC=C1 LRXXRIXDSAEIOR-ZDUSSCGKSA-N 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 229960004890 diethylpropion Drugs 0.000 description 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229940076263 indole Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960000436 phendimetrazine Drugs 0.000 description 2
- 229960003562 phentermine Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- HNOSJVWYGXOFRP-UNPOXIGHSA-N (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](O)C(C)(C)O)C)CC[C@@]21C HNOSJVWYGXOFRP-UNPOXIGHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- ZDPDQMCPRXTLIP-PAPYEOQZSA-N Alismoxide Natural products CC(C)C1=C[C@H]2[C@@H](CC[C@]2(C)O)[C@](C)(O)CC1=O ZDPDQMCPRXTLIP-PAPYEOQZSA-N 0.000 description 1
- HNOSJVWYGXOFRP-UHFFFAOYSA-N Alisol A Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(O)C(C)(C)O)C)CCC21C HNOSJVWYGXOFRP-UHFFFAOYSA-N 0.000 description 1
- GBJKHDVRXAVITG-UNPOXIGHSA-N Alisol B Chemical compound O([C@@H]1[C@@H](O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C GBJKHDVRXAVITG-UNPOXIGHSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- DORJGGFFCMZTHW-KXVAGGRESA-N C[C@H](C[C@H](O)[C@H]1OC1(C)C)C1=C2C[C@H](O)[C@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@]3(C)[C@@]2(C)CC1=O Chemical compound C[C@H](C[C@H](O)[C@H]1OC1(C)C)C1=C2C[C@H](O)[C@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@]3(C)[C@@]2(C)CC1=O DORJGGFFCMZTHW-KXVAGGRESA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- QMCLOHXDDPMAMI-UHFFFAOYSA-N alisol B Natural products CC(C)C(=O)C(O)CC(C)C1=C2CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC1 QMCLOHXDDPMAMI-UHFFFAOYSA-N 0.000 description 1
- DORJGGFFCMZTHW-UHFFFAOYSA-N alisol C Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC(=O)C=1C(C)CC(O)C1OC1(C)C DORJGGFFCMZTHW-UHFFFAOYSA-N 0.000 description 1
- SYAKTDIEAPMBAL-UHFFFAOYSA-N aminorex Chemical compound O1C(N)=NCC1C1=CC=CC=C1 SYAKTDIEAPMBAL-UHFFFAOYSA-N 0.000 description 1
- 229950002544 aminorex Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- YTJJRAWFHJBAMT-UHFFFAOYSA-N depside Natural products OC(=O)CC1=C(O)C=C(O)C=C1OC(=O)C1=CC=C(O)C(O)=C1 YTJJRAWFHJBAMT-UHFFFAOYSA-N 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种左旋肉碱绿茶减肥冲剂及其制备方法，由如下重量份的组分制成：左旋肉碱酒石酸盐50?80份，绿茶提取物10?20份，泽泻提取物10?15份，麦芽糊精15?20份，甘露醇50?70份，甜菊糖苷5?8份，魔芋精粉8?15份，茶多酚细粉10?20份，共轭亚油酸20?30份；本发明克服现有技术的不足之处，提供一种有减肥效果，并可健体的食品，该减肥冲剂不需抑制饮食，不影响人体吸收能量，不影响体力以满足人们的需要；本发明将不同作用原理的成分组合在一起，使它们以不同方式协同作用，经过复合配比，使其在减肥功能上的优势得到充分发挥；本发明同时可改善由于肥胖引起的高血压、高血脂、糖尿病等健康问题，具有增强免疫力、补气固表、改善皮肤的功效。
Description
技术领域
本发明属于保健食品技术领域，具体涉及一种左旋肉碱绿茶减肥冲剂及其制备方法。
背景技术
肥胖是一种营养代谢综合失调性疾病和低度全身慢性炎症。研究发现，肥胖病因相当复杂，不仅有明显的遗传性，还与饮食和运动密切相关。在今天肥胖已成为一个社会严重的共公卫生问题。根据世界卫生组织的统计数学显示，全球超重人数超过10亿多，有3亿多人严重肥胖，而发展中国家的肥胖比例大幅增加。在我国根据卫生部、科技部和国家统计局公布的营养与健康状况调查结果显示，我国13亿人口中有2亿人超重，特别是儿童超重迅速增长。预计今后肥胖患病率还将会有较大幅度的增长，肥胖会给国民健康造成严重的威胁，也会给个人和社会带来沉重的经济负担。
据报道，大约30-40%的现代人患有肥胖症，并且由于肥胖症经常伴随着老年疾病如高血压、高血脂、糖尿病等，因此肥胖症的治疗至关重要。另外，人们关注肥胖症的治疗及良好身体状况和体形的保持不仅是为了健康，还为了美丽。为了美丽，对能够有效去除多余的皮下脂肪、或改善皮肤的坚韧性或者弹性的减肥和抗脂肪团化妆品的需求也日益增长。
由于脂肪及其代谢废物的积累，在皮肤和皮下脂肪中形成脂肪团，脂肪团使皮肤粗糙得像橘子皮。即使肥胖症不是产生脂肪团的直接原因，但是当脂肪细胞的体积或数目变大时脂肪团就会增加，因此将脂肪细胞中的脂肪分解并去除，对于维持良好的体形和皮肤状况是非常有效的。
肥胖可以通过调整饮食、增加运动的方式进行调理，症状严重的必须进行药物治疗。国际上减肥药按作用机理可大致分为抑制食欲中枢、减少营养吸收、增加能量消耗三大类。具体品种可细分为以下几类：1)去甲肾上腺素促进剂，如：右苯丙胺、苯丁胺、安非拉酮、苄非他明、苯丙醇胺、对氯苯丁胺、苯二甲吗啉等；2)5-羟色胺促进剂，如芬氟拉明、右芬氟拉明、氟西汀等；3)同时对去甲肾上腺素和5-羟色胺有促进作用的物质，如：氯丙咪吲哚、西布曲明、氯苄雷司、利莫那班等；4)消化酶抑制剂，如奥利司他、拜糖平等；5)中枢兴奋药如麻黄碱等。其中在我国批准使用的仅有奥利司他、拜糖平、西布曲明、氯丙咪吲哚、安非拉酮等少数品种。此外，我国还有相当数量的中药品种和民间药品、食品验方。其中典型的如减肥茶(大印象、康尔寿、宁红、更娇丽等)系列产品，已经广泛应用于肥胖的调理和治疗中，深受群众欢迎。
近年来，欧美国家逐渐加强了对减肥药品安全性的管控，右苯丙胺、苯丁胺、苄非他明、对氯苯丁胺、苯二甲吗啉、芬氟拉明、右芬氟拉明、氯苄雷司、氯丙咪吲哚、阿米雷司、利莫那班、麻黄碱等品种陆续退出减肥品市。2009年美国FDA批准的可长期使用的减肥药仅有西布曲明(雅培公司)、奥利司他(罗氏公司)和阿莱(葛兰素公司)三种，这与日益强烈的减肥产品需求形成了鲜明的反差。在中国这种情况也极为突出。2010年，我国减肥原料药品种仅有西布曲明、奥利司他等少数几个，被认为是副作用和不良反应相对较轻、较为安全可靠的品种。2010年9月，国家食品药品监督管理局(SFDA)发文指出奥利司他和急性肝细胞坏死、肝衰竭、胰腺炎等症状之间存在无法排除的相关性【国食药监注[2010]359号】。同年10月，SFDA发文指出，西布曲明可能增加严重心血管风险，减肥治疗的风险大于效益。全面禁止了西布曲明的生产、销售和使用【国食药监办[2010]432号】。种种迹象表明，由于化学减肥药在安全性上存在不可避免的缺陷，肥胖的调理和治疗将更多转向中成药和保健食品。能够降低体重且具有不厌食、不腹泻、不损伤体力等优势的保健食品，有望成为减肥市场上的主流。
发明内容
本发明的目的在于克服现有技术的不足之处，提供一种有减肥效果，并可健体的食品，该减肥冲剂不需抑制饮食，不影响人体吸收能量，不影响体力以满足人们的需要。本发明将不同作用原理的成分组合在一起，使它们以不同方式协同作用，经过复合配比，使其在减肥功能上的优势得到充分发挥。本发明同时可改善由于肥胖引起的高血压、高血脂、糖尿病等健康问题，具有增强免疫力、补气固表、改善皮肤的功效。
本发明的目的是通过以下技术方案实现的：
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐50-80份，绿茶提取物10-20份，泽泻提取物10-15份，麦芽糊精15-20份，甘露醇50-70份，甜菊糖苷5-8份，魔芋精粉8-15份，茶多酚细粉10-20份，共轭亚油酸20-30份。
作为优选，左旋肉碱酒石酸盐60-70份，绿茶提取物15-20份，泽泻提取物10-12份，麦芽糊精16-20份，甘露醇60-70份，甜菊糖苷6-8份，魔芋精粉8-12份，茶多酚细粉15-18份，共轭亚油酸20-25份。
作为优选，左旋肉碱酒石酸盐50份，绿茶提取物10份，泽泻提取物10份，麦芽糊精15份，甘露醇50份，甜菊糖苷5份，魔芋精粉8份，茶多酚细粉10份，共轭亚油酸20份。
作为优选，左旋肉碱酒石酸盐80份，绿茶提取物20份，泽泻提取物15份，麦芽糊精20份，甘露醇70份，甜菊糖苷8份，魔芋精粉15份，茶多酚细粉20份，共轭亚油酸30份。
另外，本发明还提供了产品的制备方法，具体为：
按上述重量比，与上述左旋肉碱酒石酸盐，绿茶提取物，泽泻提取物，麦芽糊精，甘露醇，甜菊糖苷，魔芋精粉，茶多酚细粉，共轭亚油酸混合，搅拌均匀，制成细小颗粒，装入小袋，每小袋装3.5克，制成食疗保健减肥茶冲剂。
其中，魔芋精粉的制备方法为：将魔芋块根切片、粉碎后浸于乙醇中，在60℃下减压干燥，用石油醚脱脂，加氢氧化钠溶液溶解后过滤，滤液用盐酸中和后再加醋酸铅提取，取滤液，通入硫化氢以去除铅离子，加乙醇沉淀，离心后用丙酮干燥而得精品魔芋精粉。
茶多酚细粉的制备方法为：将乌龙茶以1∶15加入pH值4~5的酸性水中，在120℃下煮30min，过滤，合并两次滤液，浓缩、活性炭脱色、离心分离、真空干燥，得提取物茶多酚细粉。
本发明相关原料的作用和功效如下：
左旋肉碱酒石酸：左旋肉碱酒石酸盐是左旋肉碱的稳定形式，是一种促进脂肪转化为能量的类氨基酸，能促进脂肪酸进入线粒体进行氧化分解，对人体无毒副作用。左旋肉碱是参与体内脂肪代谢的重要元件，同时也可以作为抗氧化剂及自由基清除剂而发挥作用。左旋肉碱的主要功能有：1)作为载体以脂酰肉碱的形式将长链脂肪酸从线粒体膜外运送到膜内，促进脂肪酸的β-氧化，并转化为能量。由于线粒体膜对酰基-CoA衍生物的不透过性，长链脂肪酸只有与左旋肉碱酯化后才能进入线粒体内进行β-氧化；2)使短链脂酰辅酶A透过细胞膜，转移到肝脏从而被氧化或转移到肾脏被排出体外，从而防止酰化辅酶A在细胞器内过量积累而损害细胞；3)作为一种低能量有机化合物，肉碱同乙酰辅酶A形成乙酰肉碱，调节乙酰辅酶A的水平，将过量的乳酸转移出细胞，从而防止了酸中毒；4)促进碳水化合物与氨基酸的利用，参加支链氨基酸如亮氨酸、异亮氨酸等代谢产物的运输，从而有利于这些氨基酸的正常代谢。
绿茶提取物：绿茶提取物对中年人高脂血症和肥胖症有预防作用，在对平顶山市3317例参加常规体检的在职工作人员进行体格检查，统计分析饮绿茶对高脂血症和肥胖症的影响。结果显示，饮绿茶可降低中年人血清总胆固醇、低密度脂蛋白胆固醇和甘油三酯水平；而且，饮绿茶降低了中年人肥胖症患病率。经年龄、性别、吸烟量、饮酒量和锻炼时间校正后上述关系依然存在。说明，饮绿茶可预防中年人高脂血症和肥胖症。
泽泻提取物含多种四环三萜酮醇衍生物(泽泻醇A、B、C及其乙酸酯、表泽泻醇、环氧泽泻烯)，以及卵磷酯、胆碱、糖醛等。中医理论认为其性寒，具有利水渗湿的功效。现代医学研究，泽泻可降低血清总胆固醇及三酰甘油含量，减缓动脉粥样硬化形成。以上本发明技术方案中，证明泽泻对三脂酰甘油酶和胰淀粉酶有较强的抑制作用。
茶多酚包括儿茶素类，酚酸与缩酚酸类、黄酮醇类和茶色素类的化合物总称。其化学结构带有多个活性轻基，对人体具有许多保健功效。减肥、降血脂、降血压、降血糖、增强免疫力、抗菌杀菌、抗癌、抗病毒、美容养颜、保肝、抗氧化、延缓衰老等功能。
茶多酚能促进脂肪酸的氧化分解、减少脂肪在腹部的积累，还能抑制肝脏脂肪合成酶的活性，从而减少脂肪的合成及肝脏脂肪沉积，同时还能阻止脂肪在肠道的吸收，促进脂肪从粪便中排出，并能减少由碳水化合物吸收转化为脂肪引起的肥胖。
魔芋精粉：魔芋精粉有减肥作用，能明显降低体重，减小脂肪细胞大小和生殖器周围的脂肪质量。曾用魔芋精粉饲养大鼠实验，每组9只，按体重小剂量组为1.9mg/g，大剂量组为19mg/g，同时给予高脂肪、高营养饲料，共饲养45d后，进行比较，结果可见，与对照组比较大剂量组、小剂量组的体重、生殖器周围的脂重均明显降低，但大、小剂量组差异不大，在高倍显微镜下，每个视野中所见脂肪细胞数，明显多于对照组，而细胞体积明显小于对照组，说明魔芋精粉能使脂肪细胞中的脂肪含量减少，细胞挤在一起，故同样视野中的细胞数量得以增加，这说明魔芋精粉确能起到减少脂肪堆积的作用。
共轭亚油酸：共轭亚油酸是一系列含有共轭双键的亚油酸的总称，能抑制人体脂肪沉淀，促进肌肉生长，增加脂肪细胞中脂肪酸的氧化分解，减少脂肪细胞的体积，从而达到减肥的目的。
本发明的有益效果为：
（1）本发明将不同作用原理的成分左旋肉碱酒石酸盐，绿茶提取物，泽泻提取物，麦芽糊精，甘露醇，甜菊糖苷，魔芋精粉，茶多酚细粉，共轭亚油酸组合在一起，使它们以不同方式协同作用，经过复合配比，使其在减肥功能上的优势得到充分发挥，从而确保产品的功效。
（2）本发明通过抑制淀粉类物质的吸收、抑制糖吸收和转化、促进机体代谢和能量转化，增加脂肪消耗，防止脂肪形成，达到减肥功效。本发明不影响蛋白质和维生素等营养物质的吸收，无需控制饮食，即可自然控制、降低体重。
（3）本发明同时可改善由于肥胖引起的高血压、高血脂、糖尿病等健康问题，具有增强免疫力、补气固表、改善皮肤的功效。
同时本发明还提供了一种减肥产品的制备方法，工艺简单，不存在高温操作，操作方便，并且节省能源。
具体实施方式
实施例1
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐50份，绿茶提取物10份，泽泻提取物10份，麦芽糊精15份，甘露醇50份，甜菊糖苷5份，魔芋精粉8份，茶多酚细粉10份，共轭亚油酸20份。
实施例2
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐80份，绿茶提取物20份，泽泻提取物15份，麦芽糊精20份，甘露醇70份，甜菊糖苷8份，魔芋精粉15份，茶多酚细粉20份，共轭亚油酸30份。
实施例3
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐60份，绿茶提取物15份，泽泻提取物12份，麦芽糊精18份，甘露醇60份，甜菊糖苷6份，魔芋精粉11份，茶多酚细粉15份，共轭亚油酸25份。
实施例4
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐70份，绿茶提取物16份，泽泻提取物13份，麦芽糊精18份，甘露醇60份，甜菊糖苷7份，魔芋精粉10份，茶多酚细粉16份，共轭亚油酸25份。
实施例5
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐65份，绿茶提取物16份，泽泻提取物14份，麦芽糊精17份，甘露醇60份，甜菊糖苷7份，魔芋精粉14份，茶多酚细粉17份，共轭亚油酸26份。
实施例6
一种左旋肉碱绿茶减肥冲剂，由如下重量份的组分制成：左旋肉碱酒石酸盐70份，绿茶提取物19份，泽泻提取物13份，麦芽糊精16份，甘露醇59份，甜菊糖苷8份，魔芋精粉12份，茶多酚细粉14份，共轭亚油酸24份。
以上对本发明创造实施所提供的一种左旋肉碱绿茶减肥冲剂及其制备方法进行了详细的介绍，对于本领域的一般技术人员，依据本发明创造实施例的思想，在具体实施方式及应用范围上均会有改变之处，综上所述，本说明书内容不应理解为对本发明创造的限制。
Claims (8)
1.一种左旋肉碱绿茶减肥冲剂，其特征在于，由如下重量份的组分制成：左旋肉碱酒石酸盐50-80份，绿茶提取物10-20份，泽泻提取物10-15份，麦芽糊精15-20份，甘露醇50-70份，甜菊糖苷5-8份，魔芋精粉8-15份，茶多酚细粉10-20份，共轭亚油酸20-30份。
2.根据权利要求1所述的减肥冲剂，其特征在于，由如下重量份的组分制成：左旋肉碱酒石酸盐60-70份，绿茶提取物15-20份，泽泻提取物10-12份，麦芽糊精16-20份，甘露醇60-70份，甜菊糖苷6-8份，魔芋精粉8-12份，茶多酚细粉15-18份，共轭亚油酸20-25份。
3.根据权利要求1所述的减肥冲剂，其特征在于，由如下重量份的组分制成：左旋肉碱酒石酸盐50份，绿茶提取物10份，泽泻提取物10份，麦芽糊精15份，甘露醇50份，甜菊糖苷5份，魔芋精粉8份，茶多酚细粉10份，共轭亚油酸20份。
4.根据权利要求1所述的减肥冲剂，其特征在于，由如下重量份的组分制成：左旋肉碱酒石酸盐80份，绿茶提取物20份，泽泻提取物15份，麦芽糊精20份，甘露醇70份，甜菊糖苷8份，魔芋精粉15份，茶多酚细粉20份，共轭亚油酸30份。
5.一种权利要求1-4任一项所述减肥冲剂的制备方法，其特征在于，按上述重量比，与上述左旋肉碱酒石酸盐，绿茶提取物，泽泻提取物，麦芽糊精，甘露醇，甜菊糖苷，魔芋精粉，茶多酚细粉，共轭亚油酸混合。
6.搅拌均匀，制成细小颗粒，装入小袋，每小袋装3.5克，制成食疗保健减肥茶冲剂。
7.根据权利要求5所述减肥冲剂的制备方法，其特征在于，魔芋精粉的制备方法为：将魔芋块根切片、粉碎后浸于乙醇中，在60℃下减压干燥，用石油醚脱脂，加氢氧化钠溶液溶解后过滤，滤液用盐酸中和后再加醋酸铅提取，取滤液，通入硫化氢以去除铅离子，加乙醇沉淀，离心后用丙酮干燥而得精品魔芋精粉。
8.根据权利要求5所述减肥冲剂的制备方法，其特征在于，茶多酚细粉的制备方法为：将乌龙茶以1∶15加入pH值4~5的酸性水中，在120℃下煮30min，过滤，合并两次滤液，浓缩、活性炭脱色、离心分离、真空干燥，得提取物茶多酚细粉。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610122983.5A CN105724653A (zh) | 2016-03-04 | 2016-03-04 | 一种左旋肉碱绿茶减肥冲剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610122983.5A CN105724653A (zh) | 2016-03-04 | 2016-03-04 | 一种左旋肉碱绿茶减肥冲剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105724653A true CN105724653A (zh) | 2016-07-06 |
Family
ID=56249953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610122983.5A Pending CN105724653A (zh) | 2016-03-04 | 2016-03-04 | 一种左旋肉碱绿茶减肥冲剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105724653A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080251A (zh) * | 2017-04-10 | 2017-08-22 | 新乡医学院 | 一种具有减肥功能的绿茶多酚组合物及其制备方法 |
| CN109275918A (zh) * | 2017-07-19 | 2019-01-29 | 镇安县雪樱花魔芋制品有限公司 | 一种高纯度魔芋胶囊加工工艺及装置 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018832A (zh) * | 2010-11-16 | 2011-04-20 | 北京康比特体育科技股份有限公司 | 一种用于减肥的组合物及其制备方法 |
| CN104415188A (zh) * | 2013-08-19 | 2015-03-18 | 宣城柏维力生物工程有限公司 | 一种左旋肉碱茶多酚胶囊及其制备方法 |
-
2016
- 2016-03-04 CN CN201610122983.5A patent/CN105724653A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102018832A (zh) * | 2010-11-16 | 2011-04-20 | 北京康比特体育科技股份有限公司 | 一种用于减肥的组合物及其制备方法 |
| CN104415188A (zh) * | 2013-08-19 | 2015-03-18 | 宣城柏维力生物工程有限公司 | 一种左旋肉碱茶多酚胶囊及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 凌关庭: "《保健食品原料手册》", 28 February 2002, 化学工艺出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080251A (zh) * | 2017-04-10 | 2017-08-22 | 新乡医学院 | 一种具有减肥功能的绿茶多酚组合物及其制备方法 |
| CN109275918A (zh) * | 2017-07-19 | 2019-01-29 | 镇安县雪樱花魔芋制品有限公司 | 一种高纯度魔芋胶囊加工工艺及装置 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohamed et al. | Natural anti-obesity agents | |
| US8206764B2 (en) | Black soybean hull extract, method for obtaining, and use thereof | |
| CN102293430B (zh) | 一种具有抗氧化、增强免疫力的饮料及其制备方法 | |
| Rtibi et al. | Ficus carica aqueous extract alleviates delayed gastric emptying and recovers ulcerative colitis-enhanced acute functional gastrointestinal disorders in rats | |
| KR101164083B1 (ko) | 해방풍 추출물을 유효성분으로 함유하는 숙취해소용 조성물 | |
| CN114901298A (zh) | 含有植物提取物的组合物 | |
| CN101715851B (zh) | 一种减肥茶及其生产制作工艺 | |
| CN106962934A (zh) | 一种以茶皂素为主体的解酒饮料 | |
| CN115120683A (zh) | 原料组合物和中药发酵产品及其制备方法和应用 | |
| CN101642165B (zh) | 一种减肥酸奶饮料的制作方法 | |
| CN108618126A (zh) | 一种中药复方减肥特殊膳食食品及其制备方法 | |
| CN104783185B (zh) | 一种具有增强免疫力、缓解体力疲劳功能的保健食品及其制备方法 | |
| CN104415188A (zh) | 一种左旋肉碱茶多酚胶囊及其制备方法 | |
| CN105724653A (zh) | 一种左旋肉碱绿茶减肥冲剂及其制备方法 | |
| KR101394358B1 (ko) | 숙취 해소용 조성물 | |
| Na et al. | Recent trends in anti-obesity and anti-inflammatory studies in modern health care | |
| CN104872775A (zh) | 一种绿茶茶多糖复合型减肥固体饮料和应用 | |
| Lee et al. | Antihyperuricemic effect of dendropanax morbifera leaf extract in rodent models | |
| CN102552574A (zh) | 一种减肥功能的保健药物配方 | |
| Lee et al. | Effects of the red garlic extract for anti-obesity and hypolipidemic in obese rats induced high fat diet | |
| CN102596214B (zh) | 改善脂肪肝的组合物 | |
| Hong | Effects of the herb mixture, DTS20, on oxidative stress and plasma alcoholic metabolites after alcohol consumption in healthy young men | |
| CN103584095B (zh) | 治疗高血压的保健饮品及其制备方法 | |
| Kumaraswamy et al. | Scientific evaluation of anti-obesity potential of aqueous seed kernel extract of Mangifera indica Linn. in high fat diet induced obese rats | |
| RU2316973C1 (ru) | Кофе для похудения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |